Fluorescent In Situ Hybridization Probe Market To Reach $1,485.88 Million By 2030

Fluorescent In Situ Hybridization Probe Market Growth & Trends

The global fluorescent in situ hybridization probe market size is expected to reach USD 1,485.88 million by 2030, registering a CAGR of 7.78% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing global population being prone to target diseases, such as cancer, leads to the rising demand for accurate and effective diagnostics. This is expected to boost the market growth. For instance, according to the American Cancer Society Cancer Statistics 2023, it was estimated that approximately 1.9 million new cancer cases will be diagnosed in the U.S. in 2023. The Australian Institute of Health and Welfare (AIHW) 2021 report indicates that there were an estimated 150,782 new cancer cases in Australia in 2021.

Furthermore, the ICMR 2021 Report suggests that the number of cancer patients in India is projected to increase from 26.7 million in 2021 to 29.8 million in 2025. The fluorescent in situ hybridization (FISH) technique serves various purposes, including the precise localization of specific DNA sequences, genetic disease diagnosis, gene mapping, and identification of new oncogenes associated with different types of cancers. The growing investment in cancer genomics is expected to drive the adoption and significance of FISH. In addition, supportive government initiatives, rising healthcare expenditure levels, and increasing awareness pertaining to the benefits associated with this technique are expected to fuel industry growth during the forecast period.

Furthermore, technological advancement in chromogenic in situ hybridization (CISH), such as higher storage time of analyzed samples for long-duration studies, is expected to fuel the demand for navigation systems in the coming years. FISH is most commonly used in the detection of genetic diseases, such as Angelman syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down’s syndrome, Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic leukemia (ALL), and cri-du-chat. According to a publication from the CDC in 2022, Down’s syndrome is the most common genetic disorder, with almost one in every 700 newborns affected by the disorder.

The rising prevalence of the condition drives the need to provide efficient diagnostics for detecting these genetic diseases, which, in turn, drives the overall market growth. Furthermore, key participants are engaged in various strategies, such as product launches, partnerships & collaborations, and M&As, to expand their global footprint and maintain competitive position in the market. For instance, in March 2023, OGT (Sysmex Group) received IVDR certification for CytoCell FISH probes. The company is the first manufacturer of FISH probes to receive IVDR certification, showcasing its unwavering commitment to meeting the significantly more rigorous regulatory standards. This certification validates their products' enduring safety, dependability, and efficacy.

 Request a free sample copy or view report summary: Fluorescent In Situ Hybridization Probe Market Report

Fluorescent In Situ Hybridization Probe Market Report Highlights

• FLOW-FISH held the largest share of 35.81% of the fluorescent in situ hybridization probe industry in 2024 and is reported to be the fastest segment over the forecast period.

• DNA probes represent the largest segment of the market, accounting for 55.85% of revenue share, owing to their critical role in detecting specific gene sequences, chromosomal abnormalities, and structural rearrangements.

• Cancer diagnostics is the largest segment of the market, with a revenue share of 43.85% in 2024, driven by the technique’s ability to detect high precision gene rearrangements, amplifications, and deletions.

• Clinical use represents the largest segment of the market, accounting for 41.33% in 2024, driven by its widespread application in diagnosing genetic disorders, cancers, and infectious diseases.

• North America dominated the fluorescent in situ hybridization probe market and accounted for a 44.33% share in 2024, driven by the high adoption of molecular diagnostics and the strong presence of key market players.

• Asia-Pacific is rapidly emerging with a CAGR of 9.5% in the FISH probe market, driven by rising awareness of genetic diseases and increasing cancer prevalence.

Fluorescent In Situ Hybridization Probe Market Segmentation

Grand View Research has segmented the global fluorescent in situ hybridization probe market report based on technology, type, application, end-use and region:

Fluorescent In Situ Hybridization Probe Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Q FISH

• FLOW FISH

• Others

Fluorescent In Situ Hybridization Probe Type Outlook (Revenue, USD Million, 2018 - 2030)

• DNA

• RNA

  • mRNA

  • miRNA

  • Other

Fluorescent In Situ Hybridization Probe Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer Diagnostics

  • Lung

  • Breast

  • Bladder

  • Hematological

  • Gastric

  • Prostrate

  • Cervical

  • Other

• Genetic diseases

• Other

Fluorescent In Situ Hybridization Probe End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Research

• Clinical use

• Companion diagnostics

Fluorescent In Situ Hybridization Probe Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Spain

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Fluorescent In Situ Hybridization Probe Market

• Thermo Fisher Scientific Inc.

• PerkinElmer Inc.

• BioDot

• Horizon Diagnostics

• Agilent Technologies, Inc.

• Abnova Corporation

• LGC Biosearch Technologies

• Genemed Biotechnologies, Inc.

• Oxford Gene Technology IP Limited

• Biocare Medical, LLC.

• QIAGEN (Exiqon A/S)

• GSP Research Institute, Inc.